Chemomab Therapeutics Ltd ADR(CMMB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.02 | Insider Own | 4.53% | Shs Outstand | 7.3M | Perf Week | -4.76% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | -0.7% | Shs Float | 6.9M | Perf Month | 36.84% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | 0 | Inst Own | 5.35% | Short Float | 1.64% | Perf Quarter | 48.57% |
| Income | -0.01B | P/S | - | EPS this Y | -11.11% | Inst Trans | 7.11% | Short Ratio | 0.75 | Perf Half Y | 33.33% |
| Sales | 0.00B | P/B | 2.17 | EPS next 5Y | - | ROA | -71.19% | Short Interest | 0.11M | Perf YTD | 57.58% |
| Book/sh | 1.2 | P/C | 2.82 | EPS past 3/5Y | 47.24% 43.73% | ROE | -82.74% | 52W High | -27.37% ($3.58) | Perf Year | -13.04% |
| Cash/sh | 0.92 | P/FCF | - | Sales past 3/5Y | - | ROIC | -87.57% | 52W Low | 92.59% ($1.35) | Perf 3Y | -36.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 56.99% | Gross Margin | - | Volatility(W/M) | 7.63% 8% | Perf 5Y | -95.37% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.41 | EPS Q/Q | 24.16% | Profit Margin | - | RSI (14) | 64.47 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.41 | Sales Q/Q | - | SMA20 | 7.86% ($2.41) | Beta | 0.67 | Target Price | $5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/19 | SMA50 | 30.38% ($1.99) | Rel Volume | 0.16 | Prev Close | $2.69 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 98% - | SMA200 | 41.14% ($1.84) | Avg Volume(3M) | 0.15M | Price | $2.6 |
| IPO | 2019/2/12 | Option/Short | No/Yes | Trades | 229 | Volume | 23,786 | Change | -3.35% |
Company
CMMB is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧫 This is a clinical-stage Israeli biotech developing antibody therapeutics targeting chronic inflammatory and fibrotic diseases. Its lead pipeline candidate, Nevokitug (CM-101), is a monoclonal antibody that blocks CCL24, a signaling protein involved in inflammation and fibrosis. The company is listed on Nasdaq as a micro-cap ADR, having aligned with the FDA on a Phase 3 trial design for primary sclerosing cholangitis (PSC).
Over the past 1 year, roughly in the middle
27% below its 1-year high.
CMMB has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -11.1% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -36.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 5.3%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $19M.
CMMB $19M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is CMMB?
CMMB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CMMB?
The market cap of CMMB is approximately $19M, ranking 5,305 within its sector.
What is the 52-week high and low for CMMB?
CMMB has recorded a 52-week high of $3.58 and a low of $1.35.
